Concepedia

A. Patnaik

AP

Statistics

Publications

12

Citations

359

H-Index

10

Active since

2004

Affiliations

Amgen (United States)(Current)

A. Patnaik is an author at Amgen (United States) specializing in pharmacology, medicine, and oncology.

Publications per year

2004–2011

12

Publications

12

Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)

Imtiaz A. Malik, J. Randolph Hecht, A. Patnaik et al. · Journal of Clinical Oncology · 2005 · 83 citations

, , +15

A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors

A. W. Tolcher, Mace L. Rothenberg, Jordi Rodón et al. · Journal of Clinical Oncology · 2007 · 76 citations

, , +17

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

Takuya Shimizu, A. W. Tolcher, A. Patnaik et al. · Journal of Clinical Oncology · 2010 · 35 citations

, , +8

A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)

A. W. Tolcher, A. Patnaik, E Till et al. · Journal of Clinical Oncology · 2008 · 32 citations

, , +17

EZN-2968, a novel hypoxia-inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) antagonist: Results of a phase I, pharmacokinetic (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies

A. Patnaik, E. Gabriela Chiorean, Anthony Tolcher et al. · Journal of Clinical Oncology · 2009 · 27 citations

, , +12

1–5 of 12